Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6)
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.
Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.
Parenteral nutrition for patients requiring caloric and amino acid intake when oral or enteral nutrition is not possible, insufficient, or contraindicated,Off-label: May be used in specific metabolic disorders requiring controlled amino acid and dextrose delivery
Parenteral nutrition for prevention of nitrogen loss or treatment of negative nitrogen balance in patients where oral or enteral nutrition is impossible or insufficient
Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.
Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.
Not applicable as a single drug. The components have varied half-lives: amino acids have a plasma half-life of minutes to hours (e.g., alanine ~15 min); dextrose has a half-life of 1.5-2 hours under normal conditions, prolonged in renal impairment or hyperglycemia. Clinical context: in total parenteral nutrition, continuous infusion maintains steady state. No terminal half-life for the mixture.
The terminal elimination half-life of individual amino acids varies (1–4 hours) depending on metabolic demand and renal function. For the amino acid mixture, the effective half-life is approximately 2 hours in patients with normal renal function. This short half-life necessitates continuous or frequent infusion to maintain stable plasma levels.
Dextrose undergoes glycolysis and oxidation via the citric acid cycle. Amino acids are deaminated and metabolized via ureagenesis and gluconeogenesis.
Amino acids are metabolized through deamination, transamination, and decarboxylation pathways, primarily in the liver, with nitrogen converted to urea via the urea cycle and carbon skeletons entering the Krebs cycle.
The components of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER are nutrients and electrolytes that are metabolized or excreted via normal physiological pathways. Amino acids are deaminated, with nitrogen excreted primarily as urea in urine (about 90%) and a small amount in feces. Dextrose is metabolized to carbon dioxide and water, with excess exhaled as CO2 (approximately 50-70% of glucose carbon) or excreted in urine if renal threshold exceeded. Electrolytes are excreted renally in proportion to intake and homeostasis. No single excretion route percentage applies to the mixture; for amino acids, renal excretion of metabolites (urea) accounts for >90% of nitrogen elimination.
Amino acids from Aminosyn 10% are primarily utilized for protein synthesis and metabolic processes. Excess nitrogen is eliminated via the kidneys as urea (renal elimination accounts for >90% of nitrogen excretion). Minimal biliary/fecal elimination (<5%) occurs via unabsorbed amino acids in patients with malabsorption. In renal impairment, elimination is reduced.
Amino acids: variable, generally low (0-30%) bound to albumin and other plasma proteins. Dextrose: negligible protein binding. Electrolytes: calcium is ~40-50% bound to albumin and other proteins; magnesium ~30%; phosphate ~10-20%; others minimal. Overall, component-specific.
Amino acids exhibit low protein binding (<10%) to plasma proteins (primarily albumin). High-affinity binding is negligible; most amino acids circulate freely.
Not applicable as a single entity. Amino acids distribute into total body water (~0.5-0.6 L/kg). Dextrose distributes into extracellular fluid (~0.2 L/kg) initially, then intracellularly. Electrolytes distribute according to their physiological compartments. No meaningful Vd for the mixture.
Volume of distribution (Vd) for amino acids in Aminosyn 10% ranges from 0.3–0.5 L/kg, approximating total body water. This reflects extensive distribution into extracellular and intracellular compartments.
Intravenous: 100% bioavailability as it is administered directly into the bloodstream. Not applicable to oral or other routes.
Bioavailability is 100% when administered intravenously. Not applicable for oral, intramuscular, or other routes; Aminosyn 10% is for IV use only.
For GFR 30-59 m L/min: reduce volume by 25-50%; monitor electrolytes. For GFR 15-29 m L/min: reduce volume by 50-75%; avoid if severe renal impairment. For GFR <15 m L/min: contraindicated unless on renal replacement therapy; use with caution and adjust electrolytes.
For GFR 30-59 m L/min: reduce dose to 0.8-1.0 g/kg/day. For GFR 15-29 m L/min: 0.6-0.8 g/kg/day. For GFR <15 m L/min or dialysis: 0.5-0.6 g/kg/day; monitor for azotemia.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce amino acid dose by 50%; monitor ammonia. Child-Pugh Class C: avoid due to risk of hepatic encephalopathy; alternative nutrition may be needed.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 30-50% and use a formulation with higher branched-chain amino acids. Child-Pugh Class C: avoid or use with extreme caution, adjust based on ammonia levels.
Dose based on weight (kg) and caloric needs. Typical: 10-15 m L/kg/day initially, titrate to 20-30 m L/kg/day. Maximum dextrose infusion rate: 0.5 g/kg/hr for neonates, 1 g/kg/hr for older children. Use with caution in low birth weight infants.
Infants (0-1 year): 2-3 g/kg/day (20-30 m L/kg/day). Children (1-12 years): 1.5-2.5 g/kg/day (15-25 m L/kg/day). Adolescents: 1-1.5 g/kg/day (10-15 m L/kg/day). Administer as continuous IV infusion.
Elderly patients often require lower doses due to decreased renal function; start at lower infusion rates (e.g., 1-2 m L/kg/hr). Monitor fluid balance, electrolytes, and renal function closely. Dose adjustment based on GFR is recommended.
Initiate at lower end of dosing range (0.8-1 g/kg/day) due to reduced renal function and increased risk of fluid overload; monitor serum electrolytes and renal function closely.
Not for intravenous infusion unless admixed with appropriate electrolytes and vitamins. Do not administer simultaneously with blood through the same infusion site because of risk of pseudoagglutination. Use with caution in patients with severe hepatic or renal disease.
None
Monitor fluid balance, electrolyte concentrations, and acid-base status,Risk of hyperglycemia, hyperosmolarity, and metabolic acidosis,Hepatic and renal impairment require dose adjustment,Contains aluminum which may be toxic with prolonged use,Use with caution in patients with heart failure or pulmonary edema
Risk of hyperammonemia, especially in patients with hepatic impairment,Risk of metabolic acidosis,Risk of fluid overload and electrolyte imbalances,Monitor for signs of infection or phlebitis at infusion site,Use with caution in patients with renal insufficiency as may worsen azotemia
Hypersensitivity to any component,Severe hyperglycemia or diabetes mellitus with ketoacidosis,Severe hepatic or renal failure (unless adjusted),Intracranial or intraspinal hemorrhage,Anuria (for electrolyte-containing formulations)
Hypersensitivity to any component,Inborn errors of amino acid metabolism (e.g., maple syrup urine disease),Severe hepatic failure with encephalopathy,Severe azotemia or anuria
Do not administer with any oral food or enteral nutrition unless specifically ordered; interactions depend on individual patient condition. Concomitant use of oral hypoglycemic agents may require dose adjustment due to dextrose content.
No specific food interactions. However, since this is used in parenteral nutrition, oral intake may be contraindicated. Adjustments may be needed if transitioning to oral feeding.
CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, but no evidence of malformations. Second and third trimesters: no known fetal risks. However, hyperglycemia from dextrose may cause fetal macrosomia and neonatal hypoglycemia if maternal glucose control is poor.
Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studies. First trimester: No evidence of fetal harm. Second/third trimester: Use only if clearly needed; monitor maternal and fetal status.
Components are endogenous substances normally found in breast milk. Dextrose and amino acids are present in milk; no adverse effects expected. M/P ratio not established. Safe to use during breastfeeding when clinically indicated.
Excretion of amino acids into breast milk is not well studied. Considering the endogenous nature of amino acids, risk to infant is likely low if used at recommended doses. M/P ratio not determined.
Pregnancy increases plasma volume and renal clearance, but dosing adjustments are not typically required. Monitor glucose and electrolyte levels to avoid hyperglycemia or electrolyte imbalances. Use standard parenteral nutrition guidelines with close monitoring.
No specific dose adjustments required. Pregnancy may alter fluid and electrolyte needs; individualize dosing based on clinical status and laboratory parameters.
This formulation provides 4.25% amino acids and 25% dextrose with electrolytes and calcium for total parenteral nutrition. Contains sulfite-free preparation; confirm patient's sulfite allergy status. Monitor serum electrolytes, blood glucose, and liver function tests; adjust infusion rate to avoid refeeding syndrome in malnourished patients.
Aminosyn 10% (p H 6) is a crystalline amino acid solution used for parenteral nutrition. Monitor serum electrolytes, BUN, and ammonia levels due to risk of metabolic abnormalities. Adjust infusion rate to avoid hyperglycemia or hypoglycemia. Use with caution in renal or hepatic impairment. Check for compatible additives and avoid mixing with lipids in the same container unless validated.
This medication is given intravenously to provide nutrition when you cannot eat.,Report any signs of infection at the IV site: redness, swelling, pain, or fever.,You may need regular blood tests to monitor your blood sugar, electrolyte levels, and liver function.,Do not suddenly stop the infusion without consulting your healthcare provider.,Inform your healthcare provider if you have diabetes, as this solution contains dextrose (sugar).
Report any signs of infection at the IV site, such as redness, swelling, or pain.,Inform your healthcare provider if you experience nausea, vomiting, or dizziness.,This solution provides essential nutrients; do not stop treatment without consulting your doctor.,Keep an eye on your blood sugar levels if you have diabetes.,Do not take any other nutritional supplements without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER vs AMINOSYN 10% (PH6), answered by our medical review team.
CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is a Parenteral Nutrition Solution that works by CLINIMIX E 4.25/25 is a sterile, nonpyrogenic, hypertonic solution of amino acids and dextrose used for parenteral nutrition. Dextrose provides a source of calories and is metabolized to carbon dioxide and water, yielding energy. Amino acids provide building blocks for protein synthesis, tissue repair, and maintenance of nitrogen balance.. AMINOSYN 10% (PH6) is a Parenteral Nutrition Solution that works by Aminosyn 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis, helping to maintain nitrogen balance and support tissue repair and growth in patients unable to receive adequate nutrition enterally.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) depend on the specific clinical indication. These are both Parenteral Nutrition Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is: Intravenous infusion; dose is individualized based on patient's metabolic needs, weight, and clinical status. Typical adult dose: 1-2 L/day of CLINIMIX E 4.25/25 providing 4.25% amino acids and 25% dextrose. Rate of administration should not exceed 4 mg/kg/min of dextrose equivalent.. The standard adult dose of AMINOSYN 10% (PH6) is: Intravenous infusion: 1 to 1.5 g/kg/day (equivalent to 10 to 15 m L/kg/day of 10% solution) for adult patients with normal nutritional status; adjust based on metabolic needs.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER and AMINOSYN 10% (PH6) in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER is classified as Category C. CLINIMIX E 4.25/25 contains amino acids, dextrose, electrolytes, and calcium. No teratogenic effects have been reported in animal studies. In first trimester: limited human data, b. AMINOSYN 10% (PH6) is classified as Category C. Amino acids are essential nutrients; no teratogenic risk is known when used at recommended doses. However, safety during pregnancy has not been established through controlled studi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.